Literature DB >> 29607297

Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective.

Nicoletta Riva1, Walter Ageno2.   

Abstract

Entities:  

Year:  2018        PMID： 29607297      PMCID： PMC5874480          DOI： 10.2478/jtim-2018-0002

Source DB:  PubMed          Journal:  J Transl Int Med        ISSN： 2224-4018


× No keyword cloud information.
  33 in total

1.  Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis.

Authors:  Hui Chen; Lei Liu; Xingshun Qi; Chuangye He; Feifei Wu; Daiming Fan; Guohong Han
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-01       Impact factor: 2.566

2.  Vascular disorders of the liver.

Authors:  Laurie D DeLeve; Dominique-Charles Valla; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

3.  Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis.

Authors:  Lucio Amitrano; Maria Anna Guardascione; Antonella Menchise; Rossana Martino; Mariano Scaglione; Sabrina Giovine; Luigia Romano; Antonio Balzano
Journal:  J Clin Gastroenterol       Date:  2010-07       Impact factor: 3.062

Review 4.  Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies.

Authors:  Xingshun Qi; Valerio De Stefano; Hongyu Li; Junna Dai; Xiaozhong Guo; Daiming Fan
Journal:  Eur J Intern Med       Date:  2015-01-05       Impact factor: 4.487

5.  Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis.

Authors:  Yuko Nagaoki; Hiroshi Aikata; Kana Daijyo; Yuji Teraoka; Fumi Shinohara; Yuki Nakamura; Masahiro Hatooka; Kei Morio; Takashi Nakahara; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hidenori Ochi; Kazuaki Chayama
Journal:  Hepatol Res       Date:  2017-04-27       Impact factor: 4.288

6.  Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis.

Authors:  Marco Senzolo; Teresa M Sartori; Valeria Rossetto; Patrizia Burra; Umberto Cillo; Patrizia Boccagni; Daniele Gasparini; Diego Miotto; Paolo Simioni; Emmanuel Tsochatzis; Kenneth A Burroughs
Journal:  Liver Int       Date:  2012-03-21       Impact factor: 5.828

7.  Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference.

Authors: 
Journal:  Dig Liver Dis       Date:  2016-02-27       Impact factor: 4.088

8.  Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis.

Authors:  Angelo Luca; Settimo Caruso; Mariapina Milazzo; Gianluca Marrone; Giuseppe Mamone; Francesca Crinò; Luigi Maruzzelli; Roberto Miraglia; Gaetano Floridia; Giovanni Vizzini
Journal:  Radiology       Date:  2012-08-13       Impact factor: 11.105

9.  Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis.

Authors:  Jung Wha Chung; Gi Hyun Kim; Jong Ho Lee; Kyeong Sam Ok; Eun Sun Jang; Sook-Hyang Jeong; Jin-Wook Kim
Journal:  Clin Mol Hepatol       Date:  2014-12-24

10.  Spontaneous bleeding or thrombosis in cirrhosis: What should be feared the most?

Authors:  Kryssia Isabel Rodríguez-Castro; Alessandro Antonello; Alberto Ferrarese
Journal:  World J Hepatol       Date:  2015-07-18
View more
  1 in total

1.  Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.

Authors:  Ellen G Driever; Fien A von Meijenfeldt; Jelle Adelmeijer; Robbert J de Haas; Marius C van den Heuvel; Chandrasekaran Nagasami; John W Weisel; Constantino Fondevila; Robert J Porte; Anabel Blasi; Nigel Heaton; Stephen Gregory; Pauline Kane; William Bernal; Yoh Zen; Ton Lisman
Journal:  Hepatology       Date:  2021-12-05       Impact factor: 17.298
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.